EA035733B9 - Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний - Google Patents
Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеванийInfo
- Publication number
- EA035733B9 EA035733B9 EA201890325A EA201890325A EA035733B9 EA 035733 B9 EA035733 B9 EA 035733B9 EA 201890325 A EA201890325 A EA 201890325A EA 201890325 A EA201890325 A EA 201890325A EA 035733 B9 EA035733 B9 EA 035733B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- interleukin
- receptor
- peptide inhibitors
- inflammatory diseases
- treat inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 | |
| PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201890325A1 EA201890325A1 (ru) | 2018-06-29 |
| EA035733B1 EA035733B1 (ru) | 2020-07-31 |
| EA035733B9 true EA035733B9 (ru) | 2021-01-14 |
Family
ID=57757647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890325A EA035733B9 (ru) | 2015-07-15 | 2016-07-15 | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (es) |
| JP (1) | JP6858174B2 (es) |
| KR (1) | KR102513978B1 (es) |
| CN (1) | CN108348580B (es) |
| AU (1) | AU2016293619B2 (es) |
| BR (1) | BR112018000691A2 (es) |
| CA (1) | CA2991984A1 (es) |
| CL (3) | CL2018000128A1 (es) |
| CO (1) | CO2018000349A2 (es) |
| CR (1) | CR20180029A (es) |
| DO (1) | DOP2018000010A (es) |
| EA (1) | EA035733B9 (es) |
| EC (1) | ECSP18002929A (es) |
| HK (2) | HK1257747A1 (es) |
| IL (1) | IL256827A (es) |
| MX (1) | MX2018000542A (es) |
| NI (1) | NI201800008A (es) |
| PE (1) | PE20180571A1 (es) |
| PH (1) | PH12018500086A1 (es) |
| SG (1) | SG10201912066SA (es) |
| SV (1) | SV2018005614A (es) |
| UA (1) | UA123772C2 (es) |
| WO (1) | WO2017011820A2 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| ES2901704T3 (es) | 2013-03-15 | 2022-03-23 | Protagonist Therapeutics Inc | Análogos de hepcidina y usos de los mismos |
| RS56924B9 (sr) | 2013-04-19 | 2019-09-30 | Incyte Holdings Corp | Biciklični heterocikli kao fgfr inhibitori |
| EP3143037B1 (en) | 2014-05-16 | 2021-06-23 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| US9624268B2 (en) | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| BR112017006826A2 (pt) | 2014-10-01 | 2017-12-12 | Protagonist Therapeutics Inc | novos monômeros e dímeros peptídicos a4ss7 antagonistas |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX2017010673A (es) | 2015-02-20 | 2018-03-21 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CN115925790A (zh) | 2016-03-23 | 2023-04-07 | 领导医疗有限公司 | 用于合成α4β7肽拮抗剂的方法 |
| EP3570864A4 (en) * | 2017-01-18 | 2020-12-30 | Protagonist Therapeutics, Inc. | INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE IN THE TREATMENT OF FLAMMABLE DISEASES |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP3788047A2 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| CA3104418A1 (en) * | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN110015978B (zh) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2022540154A (ja) | 2019-07-10 | 2022-09-14 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| MX2022004513A (es) | 2019-10-14 | 2022-07-19 | Incyte Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CR20220285A (es) | 2019-12-04 | 2022-10-27 | Incyte Corp | Derivados de un inhibidor de fgfr |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| EP4090670A1 (en) | 2020-01-15 | 2022-11-23 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CA3226492A1 (en) * | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Bicyclic peptide inhibitors of interleukin-23 receptor |
| AU2022402440A1 (en) | 2021-12-01 | 2024-05-30 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2023172648A2 (en) * | 2022-03-09 | 2023-09-14 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (zh) * | 2022-03-17 | 2023-11-07 | 北京大学 | 订书肽、其制备方法及其制药用途 |
| WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030166514A1 (en) * | 1996-11-12 | 2003-09-04 | Jones Terence R. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| US20100190710A1 (en) * | 2007-07-06 | 2010-07-29 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
| US20130172272A1 (en) * | 2011-06-14 | 2013-07-04 | Medical Diagnostic Laboratories | Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US10416172B2 (en) * | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| WO2015054500A2 (en) * | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| US9624268B2 (en) * | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
-
2016
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/es unknown
- 2016-07-15 EA EA201890325A patent/EA035733B9/ru not_active IP Right Cessation
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/es unknown
- 2016-07-15 CR CR20180029A patent/CR20180029A/es unknown
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/ko active IP Right Grant
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 UA UAA201801482A patent/UA123772C2/uk unknown
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/pt active Search and Examination
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/ja active Active
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/zh active Active
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en active Pending
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/es unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/es unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/es unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/es unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/es unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/es unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/es unknown
-
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/zh unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/zh unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030166514A1 (en) * | 1996-11-12 | 2003-09-04 | Jones Terence R. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| US20100190710A1 (en) * | 2007-07-06 | 2010-07-29 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
| US20130172272A1 (en) * | 2011-06-14 | 2013-07-04 | Medical Diagnostic Laboratories | Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500086A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| MD3360558T2 (ro) | Compoziții care cuprind tulpini bacteriene | |
| MX2023008686A (es) | Polinucleotidos moduladores. | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MD3204025T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| MD3650033T2 (ro) | Compoziții conţinând tulpini bacteriene | |
| EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| MX2020011749A (es) | Composiciones y metodos para modular la expresion de pkk. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2022000397A (es) | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| MX2020011668A (es) | Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EA201791937A1 (ru) | Противовоспалительные полипептиды | |
| PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
| WO2016083315A8 (en) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |